Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 75Neoplasm Metastasis 9Brain Neoplasms 9Uveal Melanoma 7Skin Neoplasms 5Breast Neoplasms 4Glioblastoma 2Central Nervous System Neoplasms 2Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Second Primary 1Neoplasms 1Mycosis Fungoides 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma, Cutaneous Malignant 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Melanoma × Temozolomide × Dermatologic × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡